Blood markers may guide LAM treatment dosing
NCT ID NCT03304678
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 33 women with LAM, a rare lung disease, to find blood and urine markers that show how the drug sirolimus is working. Participants took sirolimus daily for 9 months and gave samples at the start, 3 months, and 9 months. The goal was to identify markers that could help doctors choose the right dose for each patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus (Rapamune)
What this could lead to
If successful, this could help doctors determine the best dose of sirolimus for women with LAM, potentially improving treatment and reducing side effects.
What could go wrong
This is a small, early-phase study focused on finding biomarkers, not proving the drug works. The results may not lead to a clear dosing guideline or apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHANGIOLEIOMYOMATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States